Close
Nordic 9Nordic 9

Invivo Capital (investor - Venture Capital)

Spain invivoventures.es
See something wrong or missing? Let us know
Offices:Barcelona

Invivo Capital Partners, managed by Albert Ferrer and Lluís Pareras, is a management company investing in early stages companies in the healthcare sector.

  • in 2024, Invivo Ventures announced a third fund to be closed at ​€100 million​ to be spent on innovative therapies within Spain, including cell therapy, gene therapy, and synthetic biology.
Average round investment:16.05M USD
Average number per year:3.0
Distribution: 2025 (2)2024 (1)2023 (4)2021 (1)2020 (7)
Portfolio companies: Spain Arthex Biotech S.L.Spain Integra TxDenmark Neumirna Therapeutics See the entire list
Mostly invests in: Spain Spain (12) Health services (14)
See the entire list

Showing 3 of 15 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Invivo Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Invivo Capital

Name Criteria
France Resonance VC
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United Kingdom Transition VC
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark, France
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United States Day One Ventures
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Spain, France
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
Belgium Novalis Biotech
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, France
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Netherlands Thuja Capital Management B.V.
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France Alter Equity
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.9
  • Active last 12 months: Yes
Netherlands Positron Ventures
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
France Yann Fleureau
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany Evonik Venture Capital GmbH
82%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
France L'Oreal
82%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top